OmniComm Systems® Forms Reseller Agreement with Tri-I Biotech Shanghai
OmniComm Systems, a global provider of clinical data management technology and services, announced that it has signed a reselling partnership agreement with Tri-I Biotech Shanghai Inc.
OmniComm Systems, a global provider of clinical data management technology and services, announced that it has signed a reselling partnership agreement with Tri-I Biotech Shanghai Inc., a China based consultancy providing high performance informatics solutions to over 1,000 medical and clinical research organizations across China, Hong Kong, Macau and Taiwan.
The partnership with Tri-I allows us to bring Omnicomm’s Phase I unit automation solution TrialOne to clinical pharmacology centers and Phase I units across China, with implementation services and after sales support in the local language.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
